Head-to-head evidence
BMS-986322 vs SYHX1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
BMS-986322
Developed by Bristol-Myers Squibb and partners
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
SYHX1901
Developed by CSPC Ouyi Pharmaceutical Co. and partners
NCT05858047 · Phase 2 · completed
The trial randomized 93 participants to placebo or one of three SYHX1901 doses and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical PASI 75 response at week 12, but no results are available to determine whether the comparison was met.
Next expected readout: April 2027 · NCT06943950 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMS-986322's landscape · SYHX1901's landscape